Table 1 Dose-volume requirements and constraints adopted for planning study
Targets | Optimal requirements | Mandatory |
|---|---|---|
CTV(P) Px1 = 40Gy | D98% ≥ 100% Px1 | ≥100% dose to ≥95 − 97% |
PTV(P) Px2 = 36.25Gy | D99% ≥95% Px2 V42Gy ≤ 2% | ≥95% dose to ≥98% volume V42.8Gy ≤ 2% |
PTV(SV/LN)a Px3 = 25Gy | D99% ≥95% Px3 | ≥95% dose to ≥98% volume V107% b ≤ 2% |
OARs | Optimal | Mandatory |
Bladder | V18.1Gy <40% | |
V37Gy < 5 cc | V37Gy <10 cc | |
Rectum | V18.1Gy <50% | |
V29Gy <20% | ||
V36Gy <1 cc | ||
Sigmoid | V18.1Gy <50% | |
V29Gy <20% | ||
V36Gy <1 cc | ||
Bowel | V15Gy <78 cc | V15Gy <158 cc |
V20Gy <17 cc | V20Gy <110 cc | |
V22.5Gy <14 cc | V22.5Gy <28 cc | |
V25Gy <0.5 cc | V25Gy <1 cc | |
Femoral heads | V14.5Gy <5% | |
Penile bulb | V29.5Gy <50% | |
Prostatic urethra | V42Gy < 50% | |
Neurovascular bundle | V38Gy <50% | |
Testes | Avoidance structure |